Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
HAMBURG, Germany, June 11, 2023 /PRNewswire/ A ground-breaking study was presented 10 June at the Hybrid Congress in Hamburg organized by the European Academy of Allergy & Clinical Immunology
Extended Phase 1 data reinforce the potential of NTLA-2002 to be a functional cure for people living with hereditary angioedema (HAE)Across all patients.